サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551790

結合型ワクチンの世界市場

Conjugate Vaccines

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
結合型ワクチンの世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

結合型ワクチンの世界市場は2030年までに297億米ドルに達する

2023年に186億米ドルと推定される結合型ワクチンの世界市場は、2023年から2030年にかけてCAGR 6.9%で成長し、2030年には297億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである多価結合型ワクチンは、CAGR 7.7%を記録し、分析期間終了までに210億米ドルに達すると予測されます。一価結合型ワクチンセグメントの成長率は、分析期間中CAGR 5.1%と推定されます。

米国市場は51億米ドルと推定、中国はCAGR 11.2％で成長予測

米国の結合型ワクチン市場は2023年に51億米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 11.2%で推移し、2030年には市場規模が66億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と6.9%と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界の結合型ワクチン市場- 主要動向と促進要因のまとめ

結合型ワクチンの仕組みと特徴とは？

結合型ワクチンは、特定の病原体に対する免疫反応を強化することで、細菌感染から守るように設計された特殊なワクチンです。細菌全体や不活化毒素を使用する従来のワクチンとは異なり、結合型ワクチンは弱い抗原（通常、細菌の表面に見られる多糖類）を強いタンパク質抗原に化学的に結合（コンジュゲート）させることによって作られます。この組み合わせは、免疫系が多糖類を認識し、より効果的に反応するのを助ける。多糖類だけでは強い免疫反応は起こさないが、特に免疫系がまだ発達途上の幼児には有効です。コンジュゲートタンパク質は、強固で持続的な免疫反応を刺激する担体として機能し、その結果、標的細菌に対する永続的な防御を提供する記憶細胞が産生されます。結合型ワクチンは、インフルエンザ菌b型（Hib）、肺炎球菌、髄膜炎菌などの細菌によって引き起こされる疾患の予防に大きな成功を収めており、世界中の小児予防接種プログラムの要となっています。

誰が結合型ワクチンの恩恵を受け、なぜ重要なのか？

結合型ワクチンは、深刻な細菌感染のリスクが高い乳幼児、幼児、免疫力の低下した人など、弱い立場にある人々を守るために特に重要です。これらのワクチンは、髄膜炎、肺炎、敗血症などの侵襲性細菌性疾患の発生率を大幅に減少させてきました。小児では、結合型ワクチンは定期的な予防接種の一環として投与され、小児がこれらの感染症に最もかかりやすい重要な時期に、早期かつ効果的な予防を提供します。さらに、結合型ワクチンは群衆免疫に貢献し、病原体の全体的な感染を減少させ、予防接種を受けることができない人々を保護するため、地域社会における細菌性疾患の蔓延を抑制する上で重要です。ヒブ髄膜炎や肺炎球菌感染症などの疾病の蔓延を劇的に減少させ、数え切れないほどの命を救うなど、結合型ワクチンの影響は計り知れないです。特に低・中所得国における世界・ヘルス・イニシアチブにおけるその役割は、小児死亡の予防と公衆衛生の成果の改善におけるその重要性を強調しています。

結合型ワクチンの最新の革新と動向は？

結合型ワクチンの分野は絶えず進化しており、ワクチンの有効性の向上、適用範囲の拡大、利用しやすさの向上に焦点を当てた研究開発が続けられています。最も重要な動向の一つは、1回の接種で複数の菌株や血清型の細菌を予防する多価の結合型ワクチンの開発です。このアプローチは肺炎球菌のような病原体にとって特に重要で、肺炎球菌には多数の血清型があり、以前のワクチンではカバーできなかったものもあります。その他の動向として、肺炎球菌性肺炎のような細菌感染症に対する追加的な防御の恩恵を受ける可能性のある高齢者を含む、高齢者集団への結合型ワクチンの使用拡大が挙げられます。ワクチン製剤の進歩により、これらのワクチンはより安定し、特にコールドチェーンのインフラが限られている地域では、配布が容易になってきています。さらに、新たな細菌の脅威に対応し、予防接種スケジュールを合理化するために他のワクチンと併用するための結合型ワクチンの開発に対する関心も高まっています。さらに、新たな製造技術による製造コストの削減努力により、細菌性疾患の負担が依然として大きい低所得国でも、これらのワクチンをより利用しやすくなっています。こうした技術革新は、結合型ワクチンの影響力を拡大し、細菌感染症との闘いにおける強力なツールとなっています。

結合型ワクチン市場の成長の原動力は？

結合型ワクチン市場の成長は、効果的かつ長期的な免疫戦略の必要性が高まっていることを強調するいくつかの要因によって牽引されています。主な要因は抗生物質耐性菌の増加であり、治療のみに頼るのではなく、ワクチン接種による予防の重要性が強調されています。ワクチン開発、特に多価ワクチンの開発における技術的進歩も、複数の細菌血清型に対する幅広い防御を提供することで市場の成長を促進しています。特に発展途上地域では、政府や保健機関がワクチンで予防可能な疾患による小児死亡率の低下を優先しているため、国家予防接種プログラムや世界ヘルスイニシアチブの拡大が、結合型ワクチンの採用をさらに加速させています。さらに、世界各地で高齢化が進み、特に肺炎球菌感染症に対する成人用結合型ワクチンの需要が高まっています。官民のパートナーシップに支えられ、ワクチンの入手しやすさと購入しやすさを改善するための継続的な努力も、市場拡大に寄与しています。これらの要因は、結合型ワクチンの有効性と安全性が証明されていることと相まって、市場の持続的成長を後押ししており、世界の公衆衛生活動の重要な要素となっています。

調査対象企業の例（全37件）

  • AstraZeneca PLC
  • Bharat Biotech International Ltd.
  • Biological E. Ltd.
  • Bio-Med Private Limited
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline plc.
  • GreenSignal Bio Pharma Private Limited（GSBPL）
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd.
  • Taj Pharmaceuticals Ltd.
  • Vaxcyte

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26781

Global Conjugate Vaccines Market to Reach US$29.7 Billion by 2030

The global market for Conjugate Vaccines estimated at US$18.6 Billion in the year 2023, is expected to reach US$29.7 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2023-2030. Multivalent Conjugate Vaccines, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$21.0 Billion by the end of the analysis period. Growth in the Monovalent Conjugate Vaccines segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 11.2% CAGR

The Conjugate Vaccines market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Conjugate Vaccines Market - Key Trends and Drivers Summarized

How Do Conjugate Vaccines Work and What Makes Them Unique?

Conjugate vaccines are a specialized type of vaccine designed to protect against bacterial infections by enhancing the immune response to specific pathogens. Unlike traditional vaccines that use whole bacteria or inactivated toxins, conjugate vaccines are created by chemically linking (or conjugating) a weak antigen, typically a polysaccharide found on the surface of bacteria, to a strong protein antigen. This combination helps the immune system recognize and respond more effectively to the polysaccharide, which alone would not provoke a strong immune response, especially in young children whose immune systems are still developing. The conjugated protein acts as a carrier that stimulates a robust and long-lasting immune response, resulting in the production of memory cells that provide enduring protection against the targeted bacteria. Conjugate vaccines have been highly successful in preventing diseases caused by bacteria such as Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis, making them a cornerstone of pediatric immunization programs worldwide.

Who Benefits from Conjugate Vaccines and Why Are They So Crucial?

Conjugate vaccines are particularly crucial for protecting vulnerable populations, including infants, young children, and individuals with weakened immune systems, who are at higher risk of serious bacterial infections. These vaccines have significantly reduced the incidence of invasive bacterial diseases, such as meningitis, pneumonia, and sepsis, which can have severe and sometimes fatal outcomes, particularly in young children. In pediatric populations, conjugate vaccines are administered as part of routine immunization schedules, providing early and effective protection during the critical years when children are most susceptible to these infections. Additionally, conjugate vaccines are important in controlling the spread of bacterial diseases in communities, as they contribute to herd immunity, reducing the overall transmission of pathogens and protecting those who cannot be vaccinated. The impact of conjugate vaccines has been profound, leading to dramatic declines in the prevalence of diseases like Hib meningitis and pneumococcal infections, and saving countless lives. Their role in global health initiatives, particularly in low- and middle-income countries, underscores their importance in preventing childhood mortality and improving public health outcomes.

What Are the Latest Innovations and Trends in Conjugate Vaccines?

The field of conjugate vaccines is continuously evolving, with ongoing research and development focused on improving vaccine efficacy, expanding coverage, and enhancing accessibility. One of the most significant trends is the development of multivalent conjugate vaccines that protect against multiple strains or serotypes of bacteria in a single shot. This approach is particularly important for pathogens like Streptococcus pneumoniae, which has numerous serotypes, some of which may not be covered by earlier vaccines. Another trend is the extension of conjugate vaccine use to older populations, including the elderly, who may benefit from additional protection against bacterial infections like pneumococcal pneumonia. Advances in vaccine formulation are also making these vaccines more stable and easier to distribute, particularly in regions with limited cold chain infrastructure. Moreover, there is growing interest in developing conjugate vaccines for emerging bacterial threats and for use in combination with other vaccines to streamline immunization schedules. Additionally, efforts to reduce the cost of production through novel manufacturing techniques are making these vaccines more accessible to low-income countries, where the burden of bacterial diseases remains high. These innovations are expanding the impact of conjugate vaccines, making them an even more powerful tool in the fight against bacterial infections.

What Is Driving the Growth of the Conjugate Vaccines Market?

The growth in the conjugate vaccines market is driven by several factors that highlight the increasing need for effective and long-lasting immunization strategies. A major driver is the rising incidence of antibiotic-resistant bacterial strains, which underscores the importance of prevention through vaccination rather than relying solely on treatment. Technological advancements in vaccine development, particularly in the creation of multivalent vaccines, are also propelling market growth by offering broader protection against multiple bacterial serotypes. The expansion of national immunization programs and global health initiatives, particularly in developing regions, is further accelerating the adoption of conjugate vaccines, as governments and health organizations prioritize the reduction of childhood mortality from vaccine-preventable diseases. Additionally, the aging population in many parts of the world is driving demand for adult conjugate vaccines, particularly against pneumococcal diseases, as older adults are at increased risk of severe infections. The continuous efforts to improve vaccine accessibility and affordability, supported by partnerships between public and private sectors, are also contributing to market expansion. These factors, combined with the proven efficacy and safety of conjugate vaccines, are driving sustained growth in the market, making them a critical component of global public health efforts.

Select Competitors (Total 37 Featured) -

  • AstraZeneca PLC
  • Bharat Biotech International Ltd.
  • Biological E. Ltd.
  • Bio-Med Private Limited
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline plc.
  • GreenSignal Bio Pharma Private Limited (GSBPL)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd.
  • Taj Pharmaceuticals Ltd.
  • Vaxcyte

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Conjugate Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Vaccine-Preventable Diseases Propels Growth in Conjugate Vaccines Market
    • Expanding Immunization Programs in Developing Countries Drives Adoption of Conjugate Vaccines
    • Advancements in Multivalent Vaccine Technology Strengthen Business Case for Conjugate Vaccines
    • Government and Global Health Initiatives Expand Addressable Market Opportunity for Conjugate Vaccines
    • Increasing Demand for Pediatric Vaccines Generates Growth in Conjugate Vaccines Market
    • Focus on Reducing Antibiotic Resistance Spurs Adoption of Preventive Vaccination Strategies
    • Innovations in Vaccine Formulation and Delivery Sustain Market Growth
    • Emerging Threats from New Bacterial Strains Accelerate Development of Next-Generation Conjugate Vaccines
    • Rising Geriatric Population Expands Market Potential for Adult Conjugate Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Conjugate Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Multivalent Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Multivalent Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Multivalent Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monovalent Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monovalent Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Monovalent Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Bacterial Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Bacterial Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Bacterial Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Viral Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Viral Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Viral Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Combination Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Combination Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Combination Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • JAPAN
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • CHINA
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • EUROPE
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Conjugate Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Conjugate Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • FRANCE
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • GERMANY
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Conjugate Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Conjugate Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • INDIA
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Conjugate Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Conjugate Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Conjugate Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Conjugate Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030
  • AFRICA
    • Conjugate Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Conjugate Vaccines by Vaccine Type - Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Conjugate Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Multivalent Conjugate Vaccines and Monovalent Conjugate Vaccines for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Conjugate Vaccines by Pathogen Type - Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Conjugate Vaccines by Pathogen Type - Percentage Breakdown of Value Sales for Bacterial Conjugate Vaccines, Viral Conjugate Vaccines and Combination Conjugate Vaccines for the Years 2014, 2024 & 2030

IV. COMPETITION